About 1 million women are BRCA mutation (BRCA1 or BRCA2) carriers in the US, and 85% of the carriers would develope breast cancer by the age of 60. And yet no approved drug for treating this disease. Therefore, its market potential will be bigger than that of MDS and AML combined. The market cap of CYCC could be as big as that of CELG within 10 years. Glad that the buyout did not take place recently.